Has Asciminib been launched in China?

Since Asciminib (Asciminib) was approved for marketing by the U.S. Food and Drug Administration (FDA) in October 2021, it is currently sold under the trade name Scemblix, and was approved for medical use in the European Union in August 2022. AceminiThe original drug has not yet passed the relevant national regulations and been marketed in the country. Aximinib is a tyrosine kinase inhibitor (TKI) that can be used to treat chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) pan>,It also showed benefit in Ph+CML with theT315I mutation, which creates mutant BCR-ABL1, which is often therapeutically resistant compared to wild-type BCR-ABL2.